AI Engines For more Details: Perplexity Kagi Labs You
Intestinal Amebiasis: Diloxanide furoate is the drug of choice for the treatment of asymptomatic intestinal amebiasis, which occurs when individuals harbor the Entamoeba histolytica parasite in their intestines without exhibiting symptoms. Unlike other drugs used to treat amebiasis, such as metronidazole or tinidazole, diloxanide furoate specifically targets the cyst stage of the parasite, helping to eradicate the infection and prevent its transmission to others.
Cysticidal Activity: Diloxanide furoate is a luminal amebicide, meaning it acts primarily within the lumen of the intestine to eliminate the cysts of Entamoeba histolytica. It works by inhibiting the growth and multiplication of the parasite within the intestinal tract, leading to its eventual clearance from the body.
Eradication of Infection: Treatment with diloxanide furoate helps to eradicate the Entamoeba histolytica parasite from the intestines, thereby preventing the development of symptomatic disease, such as amebic dysentery or extraintestinal amebiasis. It also reduces the risk of transmission of the parasite to others through fecal-oral contamination.
Minimal Systemic Absorption: Diloxanide furoate is poorly absorbed from the gastrointestinal tract, which limits its systemic exposure and reduces the risk of systemic side effects. This makes it a safe and well-tolerated treatment option for asymptomatic intestinal amebiasis, particularly in comparison to other medications used to treat amebiasis, which may have more significant side effects.
Side Effects: Common side effects of diloxanide furoate are generally mild and transient and may include gastrointestinal symptoms such as abdominal discomfort, nausea, vomiting, diarrhea, or flatulence. These side effects typically resolve spontaneously with continued treatment or upon completion of therapy and do not usually require discontinuation of the medication.
Contraindications: Diloxanide furoate is contraindicated in individuals with known hypersensitivity or allergy to the medication or any of its components. It should be used with caution in pregnant or breastfeeding women and in individuals with impaired hepatic function.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4 | 0.9 | 3.44 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.7 | 1.2 | 0.42 |
| Allergies | 4.2 | 2.8 | 0.5 |
| Allergy to milk products | 1.3 | 0.6 | 1.17 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.4 | 5.5 | -0.25 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.4 | 4.75 |
| Ankylosing spondylitis | 2.9 | 1.3 | 1.23 |
| Anorexia Nervosa | 1 | 2.5 | -1.5 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 4.3 | 2.1 | 1.05 |
| Atherosclerosis | 1.5 | 1.4 | 0.07 |
| Atrial fibrillation | 3.1 | 1.4 | 1.21 |
| Autism | 7.6 | 6.3 | 0.21 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 0.9 | 1.7 | -0.89 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.1 | 0.3 | 2.67 |
| Cancer (General) | 0.9 | 1.4 | -0.56 |
| Carcinoma | 3.5 | 2.2 | 0.59 |
| Celiac Disease | 1.5 | 2.9 | -0.93 |
| Cerebral Palsy | 1.2 | 1.3 | -0.08 |
| Chronic Fatigue Syndrome | 4.5 | 5.2 | -0.16 |
| Chronic Kidney Disease | 3.5 | 2.5 | 0.4 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 2 | -0.33 |
| Chronic Urticaria (Hives) | 0.6 | 0.5 | 0.2 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.3 | -3.33 |
| Cognitive Function | 3.2 | 1.4 | 1.29 |
| Colorectal Cancer | 6.4 | 2 | 2.2 |
| Constipation | 1.1 | 0.9 | 0.22 |
| Coronary artery disease | 1.3 | 2.3 | -0.77 |
| COVID-19 | 6.1 | 10 | -0.64 |
| Crohn's Disease | 5.5 | 4.9 | 0.12 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 1.4 | -1.4 | |
| deep vein thrombosis | 1.9 | 1.4 | 0.36 |
| Denture Wearers Oral Shifts | 1.6 | 1.6 | |
| Depression | 7.3 | 7.1 | 0.03 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1 | 1.1 | -0.1 |
| Endometriosis | 1.9 | 2 | -0.05 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 1.7 | 0.9 | 0.89 |
| erectile dysfunction | 0.7 | 0.3 | 1.33 |
| Fibromyalgia | 1.8 | 1.9 | -0.06 |
| Functional constipation / chronic idiopathic constipation | 3.2 | 3.3 | -0.03 |
| gallstone disease (gsd) | 1.5 | 1.2 | 0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 1.2 | 0.08 |
| Generalized anxiety disorder | 1.8 | 2.2 | -0.22 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2 | 0.7 | 1.86 |
| Graves' disease | 1.5 | 3.3 | -1.2 |
| Gulf War Syndrome | 0.7 | 0.9 | -0.29 |
| Halitosis | 1.7 | 0.3 | 4.67 |
| Hashimoto's thyroiditis | 3.4 | 1.5 | 1.27 |
| Heart Failure | 3 | 1.8 | 0.67 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.5 | 0.6 | -0.2 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
| hyperglycemia | 1.4 | 0.9 | 0.56 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.3 | 4.6 | -0.39 |
| Hypothyroidism | 0.1 | 1 | -9 |
| Hypoxia | 1.2 | 0.6 | 1 |
| IgA nephropathy (IgAN) | 1.5 | 3.8 | -1.53 |
| Inflammatory Bowel Disease | 5.5 | 6.7 | -0.22 |
| Insomnia | 2.2 | 2.6 | -0.18 |
| Intelligence | 1 | 0.3 | 2.33 |
| Intracranial aneurysms | 1 | 0.9 | 0.11 |
| Irritable Bowel Syndrome | 5.7 | 4.1 | 0.39 |
| ischemic stroke | 2.1 | 1.1 | 0.91 |
| Liver Cirrhosis | 5.6 | 4 | 0.4 |
| Long COVID | 5.4 | 6.9 | -0.28 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.5 | 1.2 | -1.4 |
| Mast Cell Issues / mastitis | 0.8 | 0.9 | -0.13 |
| ME/CFS with IBS | 0.8 | 2.3 | -1.87 |
| ME/CFS without IBS | 0.9 | 1.7 | -0.89 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 0.6 | 1.17 |
| Metabolic Syndrome | 4.9 | 5.9 | -0.2 |
| Mood Disorders | 7.1 | 5.5 | 0.29 |
| multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
| Multiple Sclerosis | 3.8 | 4.1 | -0.08 |
| Multiple system atrophy (MSA) | 0.9 | 0.7 | 0.29 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 2.7 | -8 |
| Neuropathy (all types) | 0.8 | 1.3 | -0.63 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 4.3 | -0.05 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 8.5 | 6.7 | 0.27 |
| obsessive-compulsive disorder | 4 | 3.7 | 0.08 |
| Osteoarthritis | 1.2 | 1.2 | 0 |
| Osteoporosis | 1.7 | 1.4 | 0.21 |
| pancreatic cancer | 1.1 | 0.3 | 2.67 |
| Parkinson's Disease | 6.4 | 5.4 | 0.19 |
| Polycystic ovary syndrome | 4 | 2.8 | 0.43 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 1.6 | 1.5 | 0.07 |
| Psoriasis | 2.2 | 2.1 | 0.05 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.4 | 3.8 | 0.68 |
| Rosacea | 1.2 | 0.8 | 0.5 |
| Schizophrenia | 4.8 | 2.5 | 0.92 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 1.8 | 2.1 | -0.17 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.4 | 2.5 |
| Stress / posttraumatic stress disorder | 2.1 | 2.1 | 0 |
| Systemic Lupus Erythematosus | 2.3 | 2.4 | -0.04 |
| Tic Disorder | 1.1 | 1.5 | -0.36 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.5 | 3.1 | -0.24 |
| Type 2 Diabetes | 6.2 | 5.2 | 0.19 |
| Ulcerative colitis | 3.4 | 5.1 | -0.5 |
| Unhealthy Ageing | 4.9 | 1.9 | 1.58 |
| Vitiligo | 1.5 | 1 | 0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
